Interestingly, our finding suggested the involvement of the proteasome inhibitor-Bortezomib in both canonical NF-κB and MAPK/p38 signaling pathways, highlighting TNFRSF13B as a big player in S100A9-associated myeloma progression. The gene discussed is S100A9; the disease is plasma cell myeloma.